4 Canadian pharmaceutical stocks to buy in 2021

Follow us on Google News:
 4 Canadian pharmaceutical stocks to buy in 2021
Image source: worawit,Shutterstock

The outbreak of COVID-19 has worked as a massive challenge as well as an opportunity for the pharmaceutical industry over the past year. A number of biotech and pharma companies around the world have spent significant time and funds on researching and developing various drugs and tests for the disease.


Even beyond COVID-19, many of these companies are constantly working of the innovation and manufacture of life-saving treatments. As the industry grows amid rising demand, pharma stocks are also gaining traction.

On that note, let’s look into some Canadian pharmaceutical stocks.

  1. Bausch Health Companies Inc. (TSX: BHC)

Bausch Health Companies deals in specialty drugs and medical devices. It also manufactures a range of branded generic pharmaceuticals and other over-the-counter products.

Bausch stock closed at C$ 35.9 on July 26, 2021, trading about 89 per cent above its 52-week low of C$ 14.8 (September 30, 2021). The pharma stock has increased by more than 56 per cent over the past year.

At the time of writing this, Bausch’s market cap stood at about C$ 12.5 billion.

Bausch’s total revenue was US$ 2.027 billion in the first quarter of 2021, up by about C$ 15 million year-over-year (YoY) from US$ 2.012 billion in Q1 2020.

Bausch holds a price-to-cash flow (P/CF) ratio of 7.9, as per TMX.

  1. Immunoprecise Antibodies Ltd (TSXV: IPA)

ImmunoPrecise Antibodies Ltd is engaged in the supply of custom antibodies to research and industrial enterprises.

As per the closing price of C$ 10.33 on July 26, ImmunoPrecise stock was trading about 48 per cent above its 52-week low of C$ 6.39 (July 19, 2021). While the scrip dipped by nearly 52 per cent in the last six months, it has climbed by almost 30 per cent over the past year and surged by about 28 per cent month-to-date (MTD).

ImmunoPrecise posted a revenue of $4.52 million in the third fiscal quarter ending January 31, 2021. Up by 12 per cent YoY. During this quarter, the firm closed the sale of an internally developed therapeutic antibody for the value of US$ 1.18 million.

ImmunoPrecise also received government fundings during Q3 FY21 for its COVID-related research and development projects.

ImmunoPrecise Antibodies posted a price-to-book (P/B) ratio of 5.8 and a P/CF ratio of 263.6, as per TMX.

Copyright © 2021 Kalkine Media

  1. Sernova Corp (TSXV: SVA)

A clinical-stage company, Sernova Corp is engaged in the development of treatments for chronic debilitating illnesses.

Sernova’s stock closed at a value of C$ 1.32 on July 26, recording a decline of nearly 55 per cent from its 52-week high of C$ 2.87 (January 19, 2021).

At the previous closing price, however, the pharma stock was posting a significant growth of about 420 per cent from its 52-week low of C$ 0.25 (September, 2020).

Sernova Corp posted a loss and comprehensive loss of C$ 1.66 million for the three months ending April 30, 2021. This loss, however, was narrowed from that of C$ 1.73 million in the same fiscal quarter last year.

The Canadian firm also noted a research and development expense of C$ 1.11 in the latest quarter, as per its financial results.

Sernova Corp, which featured in the 2021 Venture 50 list in February this year, holds a debt-to-equity (D/E) of 0.18 and a P/B ratio of about 11.

  1. NervGen Pharma Corp (TSXV: NGEN)

NervGen Pharma Corp is said to be engaged in the development of innovative solutions for treating nerve damage and neurodegenerative illness. The company claims to be working on drugs that can help treat Alzhiemer’s disease, spinal cord injury, etc.

NervGen Pharma, which debuted on the Toronto Stock Exchange Venture (TSXV) in March 2019, saw its stock close at a value of C$ 1.86 on July 26.

At the price, the pharma stock was trading about 31 per cent below its 52-week high of C$ 2.65 (January 27, 2021).

It was, however, holding a growth of more than 50 per cent from its 52-week low of C$ 1.21 (September 30, 2020).

NervGen Pharma’s latest quarterly report posted a net loss of $2.2 million for the first quarter of 2021, which was up from that of $1.9 million in Q1 2020.

The Q1 2021 net loss, the firm noted, included non-cash expenses of about $0.8 million.

NervGen’s cash and investments amounted to about $5 million at the end of March 2021, as compared to that of $5.6 million in the period ending December 31, 2020.

Its net cash burn from operating activities in the latest quarter, the enterprise said, stood at about $1.3 million. This, however, was partly balanced by the $0.7 million raised in net proceeds from an exercise of options and warrants that took place in Q1 2021.

NervGen holds a P/B ratio of about 14, as per TMX.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK